Peptide spiders are emerging as novel therapeutic interventions for nucleic acid delivery

Mahfoozur Rahman; Ankit Sahoo; Waleed H. Almalki; Salem Salman Almujri; Abdulmalik Saleh Alfawaz Altamimi; Abdurrahman Alhamyani; Sohail Akhter

doi:10.1016/j.drudis.2024.104021

Peptide spiders are emerging as novel therapeutic interventions for nucleic acid delivery

Mahfoozur Rahman
, Ankit Sahoo
, Waleed H. Almalki
, Salem Salman Almujri
, Abdulmalik Saleh Alfawaz Altamimi
, Abdurrahman Alhamyani
, Sohail Akhter

Pharmaceutical Chemistry

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

The FDA has approved many nucleic acid (NA)-based products. The presence of charges and biological barriers however affect stability and restrict widespread use. The electrostatic complexation of peptide with polyethylene glycol-nucleic acids (PEG-NAs) via nonreducible and reducible agents lead to three parts at one platform. The reducible linkage made detachment of siRNA from PEG easy compared with a nonreducible linkage. A peptide spider produces a small hydrodynamic particle size, which can improve drug release and pharmacokinetics. Several examples of peptide spiders that enhance stability, protection and transfection efficiency are discussed. Moreover, this review also covers the challenges, future perspectives and unmet needs of peptide-PEG-NAs conjugates for NAs delivery.

Original language	English
Article number	104021
Journal	Drug Discovery Today
Volume	29
Issue number	7
DOIs	https://doi.org/10.1016/j.drudis.2024.104021
State	Published - Jul 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
Challenges
clinical progress
gene delivery
nucleic acid
peptides
peptide–PEG conjugates
polyethylene glycol, peptide-NAs
Unmet need

Access to Document

10.1016/j.drudis.2024.104021

Cite this

@article{bd1725dec2b446528343b4f5e60bed83,

title = "Peptide spiders are emerging as novel therapeutic interventions for nucleic acid delivery",

abstract = "The FDA has approved many nucleic acid (NA)-based products. The presence of charges and biological barriers however affect stability and restrict widespread use. The electrostatic complexation of peptide with polyethylene glycol-nucleic acids (PEG-NAs) via nonreducible and reducible agents lead to three parts at one platform. The reducible linkage made detachment of siRNA from PEG easy compared with a nonreducible linkage. A peptide spider produces a small hydrodynamic particle size, which can improve drug release and pharmacokinetics. Several examples of peptide spiders that enhance stability, protection and transfection efficiency are discussed. Moreover, this review also covers the challenges, future perspectives and unmet needs of peptide-PEG-NAs conjugates for NAs delivery.",

keywords = "Cancer, Challenges, clinical progress, gene delivery, nucleic acid, peptides, peptide–PEG conjugates, polyethylene glycol, peptide-NAs, Unmet need",

author = "Mahfoozur Rahman and Ankit Sahoo and Almalki, \{Waleed H.\} and Almujri, \{Salem Salman\} and Altamimi, \{Abdulmalik Saleh Alfawaz\} and Abdurrahman Alhamyani and Sohail Akhter",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = jul,

doi = "10.1016/j.drudis.2024.104021",

language = "English",

volume = "29",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - Peptide spiders are emerging as novel therapeutic interventions for nucleic acid delivery

AU - Rahman, Mahfoozur

AU - Sahoo, Ankit

AU - Almalki, Waleed H.

AU - Almujri, Salem Salman

AU - Altamimi, Abdulmalik Saleh Alfawaz

AU - Alhamyani, Abdurrahman

AU - Akhter, Sohail

PY - 2024/7

Y1 - 2024/7

N2 - The FDA has approved many nucleic acid (NA)-based products. The presence of charges and biological barriers however affect stability and restrict widespread use. The electrostatic complexation of peptide with polyethylene glycol-nucleic acids (PEG-NAs) via nonreducible and reducible agents lead to three parts at one platform. The reducible linkage made detachment of siRNA from PEG easy compared with a nonreducible linkage. A peptide spider produces a small hydrodynamic particle size, which can improve drug release and pharmacokinetics. Several examples of peptide spiders that enhance stability, protection and transfection efficiency are discussed. Moreover, this review also covers the challenges, future perspectives and unmet needs of peptide-PEG-NAs conjugates for NAs delivery.

AB - The FDA has approved many nucleic acid (NA)-based products. The presence of charges and biological barriers however affect stability and restrict widespread use. The electrostatic complexation of peptide with polyethylene glycol-nucleic acids (PEG-NAs) via nonreducible and reducible agents lead to three parts at one platform. The reducible linkage made detachment of siRNA from PEG easy compared with a nonreducible linkage. A peptide spider produces a small hydrodynamic particle size, which can improve drug release and pharmacokinetics. Several examples of peptide spiders that enhance stability, protection and transfection efficiency are discussed. Moreover, this review also covers the challenges, future perspectives and unmet needs of peptide-PEG-NAs conjugates for NAs delivery.

KW - Cancer

KW - Challenges

KW - clinical progress

KW - gene delivery

KW - nucleic acid

KW - peptides

KW - peptide–PEG conjugates

KW - polyethylene glycol, peptide-NAs

KW - Unmet need

UR - https://www.scopus.com/pages/publications/85194956381

U2 - 10.1016/j.drudis.2024.104021

DO - 10.1016/j.drudis.2024.104021

M3 - Review article

C2 - 38750928

AN - SCOPUS:85194956381

SN - 1359-6446

VL - 29

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 7

M1 - 104021

ER -

Peptide spiders are emerging as novel therapeutic interventions for nucleic acid delivery

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this